Pitavastatin-d4-1 (sodium)

Pitavastatin-d4-1 (NK-104-d4-1) sodium is the deuterium labeled Pitavastatin sodium (HY-B0144B) . Pitavastatin (NK-104) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects[1][2][3][4].

Product Specifications

Product Name Alternative

NK-104-d4-1 (sodium)

UNSPSC

12352100

Target

Apoptosis; Autophagy; HMG-CoA Reductase (HMGCR) ; Isotope-Labeled Compounds; Mitophagy

Related Pathways

Apoptosis; Autophagy; Metabolic Enzyme/Protease; Others

Field of Research

Metabolic Disease; Neurological Disease; Cardiovascular Disease

Purity

99.22

Smiles

FC(C([2H])=C1[2H])=C([2H])C([2H])=C1C2=C(/C=C/[C@@H](O)C[C@@H](O)CC(O[Na])=O)C(C3CC3)=NC4=C2C=CC=C4

Molecular Formula

C25H19D4FNNaO4

Molecular Weight

447.47

References & Citations

[1]Morikawa S, et al. Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells. J Atheroscler Thromb. 2000;7 (3) :138-44.|[2]Katsuki S, et al. Nanoparticle-mediated delivery of pitavastatin inhibits atherosclerotic plaque destabilization/rupture in mice by regulating the recruitment of inflammatory monocytes. Circulation. 2014 Feb 25;129 (8) :896-906. |[3]Tajiri K, et al. Pitavastatin regulates helper T-cell differentiation and ameliorates autoimmune myocarditis in mice. Cardiovasc Drugs Ther. 2013 Oct;27 (5) :413-24. |[4]Sahebkar A, et al. A comprehensive review on the lipid and pleiotropic effects of pitavastatin. Prog Lipid Res. 2021 Nov;84:101127.